Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model

Erhan Kilicoglu; Ayşe Nur Hazar-yavuz; Gül Sinemcan Kabataş; Yusufhan Yazır; Levent Kabasakal

Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model

Abstract

Inflammatory bowel disease (IBD) is a complex disease with an incompletely understood multifactorial etiopathogenesis. The importance of intestinal microbiota in IBD and the role of probiotics in the treatment are being extensively investigated. This study evaluated the therapeutic effects of Bifidobacterium animalis subsp. lactis BB-12, Lactobacillus reuteri, Saccharomyces boulardii and Bacillus clausii in trinitrobenzene sulfonic acid (TNBS)-induced colitis animal model. Rats were randomly grouped into 7: control, colitis, colitis+BB-12, colitis+L. reuteri, colitis+S. boulardii, colitis+B. clausii and colitis+methylprednisolone (positive control) treatment groups. Colitis was induced by the administration of intracolonically 80 mg/kg TNBS. Treatments continued for 7 days. Body weight, stool consistency, rectal bleeding, and disease activity index (DAI) scores were evaluated and recorded daily. Macroscopic and microscopic colonic damage were evaluated and scored in the last day of experiment. Levels of malondialdehyde (MDA) and glutathione (GSH) and activity of myeloperoxidase (MPO) in the colonic tissues were detected by ELISA. Our results showed that treatments with BB-12, L. reuteri, S. boulardii and B. clausii significantly improved on clinical symptoms and decreased macroscopic and microscopic colonic damage on experimental colitis in rats. In addition, L. reuteri and S. boulardii significantly increased GSH levels and decreased MDA levels and MPO activity. When we evaluate our findings, we think that supplements of these specific probiotics may have beneficial effects in the treatment of IBD.

Keywords

References

GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020 Jan;5(1):17-30. https://doi.org/10.1016/S2468-1253(19)30333-4
Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014 Jan 7;20(1):91-9. https://doi.org/10.3748/wjg.v20.i1.91
Revés J, Ungaro RC, Torres J. Unmet needs in inflammatory bowel disease. Curr Res Pharmacol Drug Discov. 2021 Nov 30;2:100070. https://doi.org/10.1016/j.crphar.2021.100070
Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017 Apr 29;389(10080):1741-1755. https://doi.org/10.1016/S0140-6736(16)31711-1
Du L, Ha C. Epidemiology and Pathogenesis of Ulcerative Colitis. Gastroenterol Clin North Am. 2020 Dec;49(4):643-654. https://doi.org/10.1016/j.gtc.2020.07.005
Molnar T, Annaházi A. Pathogenesis of Ulcerative Colitis and Crohn’s Disease: Similarities, Differences and a Lot of Things We Do Not Know Yet. J Clin Cell Immunol. 2014;5:253. https://doi.org/10.4172/2155-9899.1000253
Rosen MJ, Dhawan A, Saeed SA. Inflammatory Bowel Disease in Children and Adolescents. JAMA Pediatr. 2015 Nov;169(11):1053-60. https://doi.org/10.1001/jamapediatrics.2015.1982
Younis N, Zarif R, Mahfouz R. Inflammatory bowel disease: between genetics and microbiota. Mol Biol Rep. 2020 Apr;47(4):3053-3063. https://doi.org/10.1007/s11033-020-05318-5

Hill C, Guarner F, Reid G, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11:506–514. https://doi.org/10.1038/nrgastro.2014.66
Yeşilyurt N, Yılmaz B, Ağagündüz D, Capasso R. Involvement of Probiotics and Postbiotics in the Immune System Modulation. Biologics. 2021;1:89-110. https://doi.org/10.3390/biologics1020006
Kim SK, Guevarra RB, Kim YT, et al. Role of Probiotics in Human Gut Microbiome-Associated Diseases. J Microbiol Biotechnol. 2019 Sep 28;29(9):1335-1340. https://doi.org/10.4014/jmb.1906.06064
Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017 Dec 23;390(10114):2769-2778. https://doi.org/10.1016/S0140-6736(17)32448-0
Zhao M, Gönczi L, Lakatos PL, Burisch J. The Burden of Inflammatory Bowel Disease in Europe in 2020. J Crohns Colitis. 2021 Sep 25;15(9):1573-1587. https://doi.org/10.1093/ecco-jcc/jjab029
Tian T, Wang Z, Zhang J. Pathomechanisms of Oxidative Stress in Inflammatory Bowel Disease and Potential Antioxidant Therapies. Oxid Med Cell Longev. 2017;2017:4535194. https://doi.org/10.1155/2017/4535194
Cai Z, Wang S, Li J. Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Front Med (Lausanne). 2021 Dec 20;8:765474. https://doi.org/10.3389/fmed.2021.765474
McFarland LV, Evans CT, Goldstein EJC. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2018 May 7;5:124. https://doi.org/10.3389/fmed.2018.00124
Kilicoglu E. Prebiotics and Probiotics. In: Sener G, Goren ZM, Okuyan B, Yegen CB (Eds). Güncel Farmakoloji Fizyoloji Temelinde Hasta Odaklı Yaklaşım. Güneş Kitabevi, Ankara, 2022, pp. 894-897.
Jonkers D, Penders J, Masclee A, Pierik M. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs. 2012 Apr 16;72(6):803-23. https://doi.org/10.2165/11632710-000000000-00000
Martyniak A, Medyńska-Przęczek A, Wędrychowicz A, Skoczeń S, Tomasik PJ. Prebiotics, Probiotics, Synbiotics, Paraprobiotics and Postbiotic Compounds in IBD. Biomolecules. 2021 Dec 18;11(12):1903. https://doi.org/10.3390/biom11121903
Wang Y, Wu Y, Wang Y, et al. Antioxidant Properties of Probiotic Bacteria. Nutrients. 2017 May 19;9(5):521. https://doi.org/10.3390/nu9050521
Antoniou E, Margonis GA, Angelou A, et al. The TNBS-induced colitis animal model: An overview. Ann Med Surg (Lond). 2016 Aug 19;11:9-15. https://doi.org/10.1016/j.amsu.2016.07.019
Silva I, Solas J, Pinto R, Mateus V. Chronic Experimental Model of TNBS-Induced Colitis to Study Inflammatory Bowel Disease. Int J Mol Sci. 2022 Apr 25;23(9):4739. https://doi.org/10.3390/ijms23094739
Dodda D, Chhajed R, Mishra J, Padhy M. Targeting oxidative stress attenuates trinitrobenzene sulphonic acid induced inflammatory bowel disease like symptoms in rats: role of quercetin. Indian J Pharmacol. 2014 May-Jun;46(3):286-91. https://doi.org/10.4103/0253-7613.132160
Kim JJ, Shajib MS, Manocha MM, Khan WI. Investigating intestinal inflammation in DSS-induced model of IBD. J Vis Exp. 2012 Feb 1;(60):3678. https://doi.org/10.3791/3678
Javed NH, Alsahly MB, Khubchandani J. Oral Feeding of Probiotic Bifidobacterium infantis: Colonic Morphological Changes in Rat Model of TNBS-Induced Colitis. Scientifica (Cairo). 2016;2016:9572596. https://doi.org/10.1155/2016/9572596
Satish Kumar CS, Kondal Reddy K, Boobalan G, et al. Immunomodulatory effects of Bifidobacterium bifidum 231 on trinitrobenzenesulfonic acid-induced ulcerative colitis in rats. Res Vet Sci. 2017 Feb;110:40-46. https://doi.org/10.1016/j.rvsc.2016.10.010
Utku OG, Karatay E, Ergul B, et al. Is the Probiotic Mixture Effective in the Treatment of TNBS-induced Experimental Colitis? JAREM. 2020;10(1):41-7. https://doi.org/10.4274/jarem.galenos.2019.2247
Chen LL, Wang XH, Cui Y, et al. Therapeutic effects of four strains of probiotics on experimental colitis in mice. World J Gastroenterol. 2009 Jan 21;15(3):321-7. https://doi.org/10.3748/wjg.15.321
Jakubczyk D, Leszczyńska K, Górska S. The Effectiveness of Probiotics in the Treatment of Inflammatory Bowel Disease (IBD)-A Critical Review. Nutrients. 2020 Jul 2;12(7):1973. https://doi.org/10.3390/nu12071973
Wilkins T, Sequoia J. Probiotics for Gastrointestinal Conditions: A Summary of the Evidence. Am Fam Physician. 2017 Aug 1;96(3):170-178. PMID: 28762696
Sha S, Xu B, Kong X, et al. Preventive effects of Escherichia coli strain Nissle 1917 with different courses and different doses on intestinal inflammation in murine model of colitis. Inflamm Res. 2014 Oct;63(10):873-83. https://doi.org/10.1007/s00011-014-0761-1
Soyturk M, Saygili SM, Baskin H, et al. Effectiveness of Saccharomyces boulardii in a rat model of colitis. World J Gastroenterol. 2012 Nov 28;18(44):6452-60; discussion p. 6459. https://doi.org/10.3748/wjg.v18.i44.6452
Ackerman Z, Karmeli F, Cohen P, Rachmilewitz D. Experimental colitis in rats with portal hypertension and liver disease. Inflamm Bowel Dis. 2003 Jan;9(1):18-24. https://doi.org/10.1097/00054725-200301000-00003

Details

Primary Language

English

Subjects

Medical Pharmacology

Journal Section

Research Article

Authors

Erhan Kilicoglu ^* This is me
0000-0002-3853-0408
Türkiye

Ayşe Nur Hazar-yavuz
0000-0003-0784-8779
Türkiye

Gül Sinemcan Kabataş
0000-0003-2168-1629
Türkiye

Yusufhan Yazır
0000-0002-8472-0261
Türkiye

Levent Kabasakal
0000-0002-5474-6436
Türkiye

Publication Date

June 28, 2025

Submission Date

February 23, 2023

Acceptance Date

March 8, 2023

Published in Issue

Year 2023 Volume: 27 Number: 4

IZ

https://izlik.org/JA73LX25UB

Cite

RIS / Bibtex

APA

Kilicoglu, E., Hazar-yavuz, A. N., Kabataş, G. S., Yazır, Y., & Kabasakal, L. (2025). Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model. Journal of Research in Pharmacy, 27(4), 1626-1637. https://izlik.org/JA73LX25UB

AMA

1.Kilicoglu E, Hazar-yavuz AN, Kabataş GS, Yazır Y, Kabasakal L. Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model. J. Res. Pharm. 2025;27(4):1626-1637. https://izlik.org/JA73LX25UB

Chicago

Kilicoglu, Erhan, Ayşe Nur Hazar-yavuz, Gül Sinemcan Kabataş, Yusufhan Yazır, and Levent Kabasakal. 2025. “Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model”. Journal of Research in Pharmacy 27 (4): 1626-37. https://izlik.org/JA73LX25UB.

EndNote

Kilicoglu E, Hazar-yavuz AN, Kabataş GS, Yazır Y, Kabasakal L (July 1, 2025) Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model. Journal of Research in Pharmacy 27 4 1626–1637.

IEEE

[1]E. Kilicoglu, A. N. Hazar-yavuz, G. S. Kabataş, Y. Yazır, and L. Kabasakal, “Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model”, J. Res. Pharm., vol. 27, no. 4, pp. 1626–1637, July 2025, [Online]. Available: https://izlik.org/JA73LX25UB

ISNAD

Kilicoglu, Erhan - Hazar-yavuz, Ayşe Nur - Kabataş, Gül Sinemcan - Yazır, Yusufhan - Kabasakal, Levent. “Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model”. Journal of Research in Pharmacy 27/4 (July 1, 2025): 1626-1637. https://izlik.org/JA73LX25UB.

JAMA

1.Kilicoglu E, Hazar-yavuz AN, Kabataş GS, Yazır Y, Kabasakal L. Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model. J. Res. Pharm. 2025;27:1626–1637.

MLA

Kilicoglu, Erhan, et al. “Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model”. Journal of Research in Pharmacy, vol. 27, no. 4, July 2025, pp. 1626-37, https://izlik.org/JA73LX25UB.

Vancouver

1.Erhan Kilicoglu, Ayşe Nur Hazar-yavuz, Gül Sinemcan Kabataş, Yusufhan Yazır, Levent Kabasakal. Comparison of the Effectiveness of Probiotics in the Experimental Colitis Model. J. Res. Pharm. [Internet]. 2025 Jul. 1;27(4):1626-37. Available from: https://izlik.org/JA73LX25UB